PapersFlow Research Brief
Bone health and treatments
Research Guide
What is Bone health and treatments?
Bone health and treatments refer to the maintenance of skeletal integrity and therapeutic interventions, including bisphosphonates, to manage bone metastases, prevent skeletal complications, and treat conditions like osteoporosis in cancer patients, particularly those with prostate and breast cancer.
This field encompasses 87,464 papers on bisphosphonates for bone metastases and complications such as osteonecrosis of the jaw. Research details mechanisms of action, clinical guidelines, and applications in prostate and breast cancer treatments. Studies emphasize preventing skeletal-related events while addressing osteoclast activity and bone resorption processes.
Topic Hierarchy
Research Sub-Topics
Bisphosphonates in Bone Metastases Treatment
Clinical trials assess zoledronic acid and pamidronate for delaying skeletal-related events in breast and prostate cancer. Research compares dosing regimens and combination with antiresorptives.
Osteonecrosis of the Jaw with Bisphosphonates
Studies investigate incidence, risk factors like dental procedures, and pathophysiology of BRONJ in cancer patients. Management guidelines and preventive strategies are systematically reviewed.
Osteoclast Differentiation Mechanisms
Molecular research elucidates RANKL/RANK/OPG signaling pathways and transcription factors regulating osteoclastogenesis. In vitro and animal models identify therapeutic targets for bone resorption.
Bisphosphonates in Prostate Cancer Bone Disease
Trials evaluate bisphosphonates adjunctive to androgen deprivation for preventing fractures and pain in metastatic prostate cancer. Biomarkers predict response and progression-free survival.
Denosumab versus Bisphosphonates Comparison
Head-to-head RCTs compare RANKL inhibitor denosumab with bisphosphonates for SRE prevention in solid tumors. Analyses address renal safety, hypocalcemia risks, and cost-effectiveness.
Why It Matters
Bisphosphonates maintain bone health in cancer patients by inhibiting osteoclasts, reducing skeletal complications from bone metastases in prostate and breast cancer. "Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer" (2004) by Tannock et al. showed docetaxel with prednisone improved survival, pain relief, PSA levels, and quality of life compared to mitoxantrone plus prednisone in advanced prostate cancer patients. Alendronate reduced fracture risk in women with vertebral fractures, as demonstrated in "Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures" (1996) by Black et al. Parathyroid hormone (1-34) decreased vertebral and nonvertebral fracture risk while increasing bone mineral density in postmenopausal osteoporosis, per "Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis" (2001) by Neer et al., supporting anabolic treatments alongside antiresorptive bisphosphonates.
Reading Guide
Where to Start
"Osteoclast differentiation and activation" (2003) by Boyle et al., as it provides foundational understanding of osteoclast biology central to bone resorption in health and disease, cited 6483 times.
Key Papers Explained
"Osteoclast differentiation and activation" (2003) by Boyle et al. establishes osteoclast mechanisms, built upon by "Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation" (1998) by Lacey et al. identifying RANKL, and "Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL" (1998) by Yasuda et al. confirming its role. "Bone Resorption by Osteoclasts" (2000) by Teitelbaum links this to osteoporosis pathology. "Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures" (1996) by Black et al. applies antiresorptive therapy clinically, while "Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer" (2004) by Tannock et al. extends to cancer skeletal complications.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current focus remains on bisphosphonate mechanisms in bone metastases and guidelines like those in "Clinician’s Guide to Prevention and Treatment of Osteoporosis" (2014) by Cosman et al., with no recent preprints or news available.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Osteoclast differentiation and activation | 2003 | Nature | 6.5K | ✕ |
| 2 | Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for ... | 2004 | New England Journal of... | 5.7K | ✕ |
| 3 | Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast... | 1998 | Cell | 5.4K | ✓ |
| 4 | Effect of Parathyroid Hormone (1-34) on Fractures and Bone Min... | 2001 | New England Journal of... | 4.5K | ✕ |
| 5 | Osteoclast differentiation factor is a ligand for osteoprotege... | 1998 | Proceedings of the Nat... | 4.2K | ✓ |
| 6 | Osf2/Cbfa1: A Transcriptional Activator of Osteoblast Differen... | 1997 | Cell | 4.2K | ✓ |
| 7 | Clinician’s Guide to Prevention and Treatment of Osteoporosis | 2014 | Osteoporosis Internati... | 4.0K | ✓ |
| 8 | Bone Resorption by Osteoclasts | 2000 | Science | 3.9K | ✕ |
| 9 | Randomised trial of effect of alendronate on risk of fracture ... | 1996 | The Lancet | 3.8K | ✕ |
| 10 | The diagnosis of osteoporosis | 1994 | Journal of Bone and Mi... | 3.8K | ✕ |
Frequently Asked Questions
What role do osteoclasts play in bone health?
Osteoclasts resorb bone, and their imbalance with formation contributes to osteoporosis and bone metastases. "Bone Resorption by Osteoclasts" (2000) by Teitelbaum explains osteoclasts as specialized cells targeting bone resorption in skeletal turnover. "Osteoclast differentiation and activation" (2003) by Boyle et al. details their differentiation regulated by cytokines like RANKL.
How do bisphosphonates treat bone metastases?
Bisphosphonates inhibit osteoclast activity to prevent skeletal complications in cancer patients with bone metastases. They target metastatic bone disease in prostate and breast cancer, reducing events like fractures. Clinical practice guidelines recommend their use for bone health maintenance.
What is the effect of alendronate on fractures?
Alendronate reduces fracture risk in women with existing vertebral fractures. "Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures" (1996) by Black et al. confirmed its efficacy through a randomised trial. It serves as an antiresorptive treatment in osteoporosis management.
How does parathyroid hormone treat osteoporosis?
Parathyroid hormone (1-34) at 40-microg dose decreases vertebral and nonvertebral fracture risk and increases bone mineral density. "Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis" (2001) by Neer et al. showed superior effects over the 20-microg dose. It is well-tolerated for postmenopausal osteoporosis.
What defines osteoporosis diagnosis?
Osteoporosis diagnosis relies on bone mineral density measurements and fracture risk assessment. "The diagnosis of osteoporosis" (1994) by Kanis et al. outlines criteria for identifying the condition. "Clinician’s Guide to Prevention and Treatment of Osteoporosis" (2014) by Cosman et al. provides guidelines for prevention and management.
What regulates osteoclast differentiation?
Osteoprotegerin ligand (RANKL) regulates osteoclast differentiation and activation from monocyte/macrophage lineage. "Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation" (1998) by Lacey et al. identifies it as a key cytokine. "Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL" (1998) by Yasuda et al. confirms its identity to TRANCE/RANKL.
Open Research Questions
- ? How can bisphosphonate-related osteonecrosis of the jaw be prevented in cancer patients with bone metastases?
- ? What are the long-term effects of combining bisphosphonates with anabolic agents like parathyroid hormone in osteoporosis treatment?
- ? Which molecular pathways beyond RANKL regulate osteoclast activation in metastatic bone disease?
- ? How do prostate cancer treatments like docetaxel impact skeletal complications compared to traditional chemotherapies?
- ? What biomarkers predict response to bisphosphonates in breast cancer bone metastases?
Recent Trends
The field maintains steady emphasis on bisphosphonates for bone metastases with 87,464 papers total, though 5-year growth data is unavailable.
Highly cited works like "Osteoclast differentiation and activation" by Boyle et al. (6483 citations) and "Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer" (2004) by Tannock et al. (5672 citations) continue to underpin research.
2003No recent preprints or news coverage reported in the last 6-12 months.
Research Bone health and treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Bone health and treatments with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers